2015 Antineoplastics

3. ANTIBODIES and FUSION PROTEINS

As molecular targets are identified that distinguish cancer cells from normal cells, monoclonal antibodies have been developed that can selectively recruit the immune system to destroy the cancer cells.  Currently, antibodies have been designed that target CDs (CD20 in NHL and CD52 in B-CLL), and cell surface proteins (HER2, VEGF, EGFR) that are overexpressed in specific cancers.

Critical facts icon
TARGET
DRUG
USE
CD20
RITUXIMAB
IBRITUMOMAB (90Y)
TOSITUMOMAB (131I)
CD52
ALEMTUZUMAB
B-cell chronic lymphocytic leukemia (B-CLL)

DENILEUKIN DIFTITUX

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 10-may-15 3:17 PM